Sprint Bioscience ABOSTO:SPRINT -4.92%32 Median PS Value is kr6.05 as of Jul. 03, 2026, which is 100% below its 10-year median of 0.20. GuruFocus rates OSTO:SPRINT with a GF Score™ of 32/100 and a GF Value™ of kr2.18 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 277 Biotechnology companies, Sprint Bioscience AB ranks worse than 51.26% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Sprint Bioscience AB's Median PS Value or its related term are showing as below:
OSTO:SPRINT'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2 Med: 0.2 Max: 0.74
Current: 0.67
During the past 13 years, the highest Price to Median PS Value of Sprint Bioscience AB was 0.74. The lowest was 0.20. And the median was 0.20.
OSTO:SPRINT's Price-to-Median-PS-Value is ranked worse than 51.26% of 277
companies
in the Biotechnology industry
Industry Median: 0.66
vs OSTO:SPRINT: 0.67
Sprint Bioscience AB (OSTO:SPRINT) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Sprint Bioscience AB's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
4.06
/
6.05
=
0.67
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB Median PS Value Related Terms
Sprint Bioscience AB Median PS Value Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 4.1017.
Sprint Bioscience AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.475.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a Median PS Value of kr6.05 as of Jul. 03, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sprint Bioscience AB and its competitors. This is 2925% above median its historical median of 0.20. Over the past decade, Sprint Bioscience AB's Median PS Value has ranged from 0.20 to 0.74. According to the industry distribution chart, Sprint Bioscience AB ranks #142 out of 277 companies in the Biotechnology industry, placing it in the top 51.3%.
Is Sprint Bioscience AB's Median PS Value too high?
Sprint Bioscience AB's current Median PS Value of kr6.05 is 2925% above median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.20 to a high of 0.74. Based on the distribution chart, Sprint Bioscience AB ranks #142 out of 277 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #142 out of 277 companies for Median PS Value. This places Sprint Bioscience AB in the lower half of its industry. The industry median Median PS Value is 0.66. Historically, Sprint Bioscience AB's own Median PS Value has ranged from 0.20 to 0.74 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.66, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median Median PS Value is 0.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current Median PS Value is kr6.05, which is 2925% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.06 — trading 86.2% above its estimated fair value. The current Median PS Value is kr6.05, which is 2925% above median its 10-year median of 0.20. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current Median PS Value is kr6.05 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?
Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued.
The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18.
GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPRINT:
Median PS Value: kr6.05 (2925% above median its 10-year median of 0.20)
GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score
Get the complete analysis for OSTO:SPRINT
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
